the aims of this article are to provide an update on our clinical programs and anticipate anticipated milestones through the end of this year and into 2016. the aims of this meeting are to provide an update on our clinical programs, including the first of two important milestones from our phase 3 f Finability trial, the second of two important milestones from our phase 3 synergy trial, and the second of two important milestones from the enprra - enprra - aas - enprra. the second part of this review will provide an overview of our financial results for the second quarter and we will conclude the call with questions.